ERIS - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.3
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be between 1,340 ₹ and 1,380 ₹ , utilizing the resistance level established by the DMA 50. An exit zone would be around 1,280 ₹ if the downward trend reasserts itself or if the stock fails to sustain momentum above the 1,380 ₹ level. Overall, with the extremely high valuation and recent negative profit figures, a cautious approach is warranted – this is a trading opportunity more than an investment based on current charts alone.
✅ Positive
The price action shows a recent bounce off the 1,200 ₹ low with increasing volume suggesting renewed buying interest. The RSI at 42.6 indicates the stock is neither overbought nor oversold, positioning it for further movement within its range.
⚠️ Limitation
Despite the recent uptick and positive volume, the extremely high Stock P/E of 88.0 relative to the Industry PE of 34.8 suggests significant premium valuation concerns. This could be a major risk if the stock fails to justify this multiple, potentially leading to a sharp correction. The negative profit in the previous quarter also weighs on the outlook.
📉 Company Negative News
Recent news reveals that Eris Lifesciences has partnered with Natco Pharma for the launch of semaglutide in India – typically this is positive, but it’s unclear whether these sales will immediately translate into strong profits or if there's a significant investment period ahead. Value Research reports a Qtr Profit Variance (-51.7%) which reflects an unfavourable comparison to the previous quarter.
📈 Company Positive News
The partnership with Natco Pharma for semaglutide launch in India signals potential future growth and expanded market reach, potentially supporting the stock price in the long run.
🏭 Industry
The pharmaceutical sector, particularly within diabetes treatment (given Eris Lifesciences’ focus), is generally considered a stable industry but competitive. High P/E multiples are common for innovative drug companies with strong growth prospects, however this company is currently exhibiting negative profit trends, which reduces the attractiveness of this valuation.